The Bellvitge Biomedical Research Institute (IDIBELL) would like to state that, in accordance with the new responsibility of Dr Manel Esteller as director of the Josep Carreras Leukaemia Research Institute (IJC), the Cancer Epigenetics and Biology Program (PEBC) that he has led at IDIBELL so far has been discontinued. IDIBELL research groups led by Dr Montserrat Sanchez-Cespedes, Dr Àlex Vaquero, Dr Esteban Ballestar, Dr Maribel Parra and Dr Sònia Guil will also become part of the IJC in the near future.

 

The PEBC was launched at IDIBELL in 2009. Dr Manel Esteller, ICREA researcher and professor at the University of Barcelona, has coordinated it since its inception. Throughout these ten years, researchers and staff of this research program have proven their talent, perseverance and productivity, which has resulted in excellent research and a wide recognition, both scientific and social.

 

 

IDIBELL has firmly given its support to the task carried out by Dr Esteller and the entire team of PEBC researchers and staff. The institute appreciates the work carried out by all these professionals, and reasserts its support to those who will still be linked to the institution within other research programs. Likewise, the Board and the management of IDIBELL wish Dr Esteller and the researchers who join him good luck and success in their new venture at the IJC. In this context of changes and opportunities, they hope that the experience gained at IDIBELL will help them face all upcoming challenges in the most appropriate way.

 

Research, innovation and society are the foundations of IDIBELL; thousands of researchers and professionals have worked, work and will work tirelessly to generate and share knowledge in order to improve people’s health. The Institute would like to thank them for their contribution in the definition of one of the most important biosanitary research and healthcare hubs in the country.